Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a ...

Travere Therapeutics has turned music mogul, bringing together a singer-songwriter and Grammy-winning producer to create an ...

Travere Therapeutics focuses on rare kidney and metabolic diseases, with strong revenue growth from recently approved Filspari and a narrowing loss in Q1 2024. Analysts generally remain bullish ...

SAN DIEGO, June 11, 2025--Travere Therapeutics today announced that the Company will present three abstracts at the upcoming International Podocyte Conference. SAN DIEGO, June 10, 2025--Travere ...

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Travere Therapeutics (NASDAQ:TVTX) in the last three months. In the table below, you'll find ...

Travere Therapeutics (NASDAQ:TVTX), a biopharmaceutical company focused on developing therapies for rare diseases, finds itself at a critical juncture as it navigates regulatory challenges and ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees ...